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PROMISE: a real-world clinical-genomic database to address
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PURPOSE: Prostate cancer is a heterogeneous disease with variable clinical outcomes. Despite numerous recent approvals of novel
therapies, castration-resistant prostate cancer remains lethal. A “real-world” clinical-genomic database is urgently needed to
enhance our characterization of advanced prostate cancer and further enable precision oncology.
METHODS: The Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) is a consortium whose aims
are to establish a repository of de-identiﬁed clinical and genomic patient data that are linked to patient outcomes. The consortium
structure includes a (1) bio-informatics committee to standardize genomic data and provide quality control, (2) biostatistics
committee to independently perform statistical analyses, (3) executive committee to review and select proposals of relevant
questions for the consortium to address, (4) diversity/inclusion committee to address important clinical questions pertaining to
racial disparities, and (5) patient advocacy committee to understand patient perspectives to improve patients’ quality of care.
RESULTS: The PROMISE consortium was formed by 16 academic institutions in early 2020 and a secure RedCap database was
created. The ﬁrst patient record was entered into the database in April 2020 and over 1000 records have been entered as of early
2021. Data entry is proceeding as planned with the goal to have over 2500 patient records by the end of 2021.
CONCLUSIONS: The PROMISE consortium provides a powerful clinical-genomic platform to interrogate and address data gaps that
have arisen with increased genomic testing in the clinical management of prostate cancer. The dataset incorporates data from
patient populations that are often underrepresented in clinical trials, generates new hypotheses to direct further research, and
addresses important clinical questions that are otherwise difﬁcult to investigate in prospective studies.
Prostate Cancer and Prostatic Diseases; https://doi.org/10.1038/s41391-021-00433-1

INTRODUCTION
Despite advances in treatment, the median overall survival from
onset of metastatic castrate-resistant prostate cancer (mCRPC)
remains dismal [1]. In this subset of patients, there is a variable
response to currently available therapies, and treatment in these
men has not historically been guided by molecular biomarkers.
Over the last decade, advancements in genomic sequencing
technologies have allowed for a deeper understanding of the
molecular complexity of this disease. Many potentially actionable
alterations are now identiﬁed, fueling biomarker-based clinical
trials of novel molecularly targeted agents as well as standard

therapies. An important example of genomically tailored therapy
in prostate cancer is the utility of Poly-(ADP ribose) polymerase
(PARP) inhibitors in patients whose tumors harbor Homologous
Recombination Repair (HRR) defects. The demonstrated clinical
efﬁcacy of olaparib [2] and rucaparib [3] in metastatic CRPC with
HRR defects and their subsequent approval by the US Food and
Drug Administration (FDA) marked an important milestone in the
implementation of precision medicine for this disease.
The approvals of PARP inhibitors make it imperative to obtain
somatic sequencing for all men with advanced prostate cancer. In
addition, germline testing is also recommended for all men with
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metastatic prostate cancer per National Comprehensive Cancer
Network guidelines, and in selected men with localized disease
based on clinical risk and histologic subtypes as well as family
history [4]. In fact, germline mutations in HRR genes exists in ~5%
of localized prostate cancer [5]. In addition, multiple guideline
panels recommend genomic sequencing for all patients with
advanced prostate cancer. With this shifting paradigm and
advancements in technology, there will be a rise in availability,
breadth, and scope of genomic data derived from CLIA-based
testing platforms. Linkage of such data with granular patient
outcomes can be leveraged to improve our understanding of the
molecular mechanisms that lead to variable clinical outcomes
across prostate cancer disease states over time, identify additional
subgroups of patients whose tumors are more vulnerable to
speciﬁc therapies, and help guide decisions of optimal sequencing
of therapies in prostate cancer.
The Prostate Cancer Precision Medicine Multi-Institutional
Collaborative Effort (PROMISE) is a consortium of academic cancer
centers with the goal of better deﬁning the clinical-genomic
features across the entire prostate cancer disease spectrum.
Herein, we outline the rationale, design, and objectives of our
multi-institutional, retrospective clinical-genomic database of
advanced prostate cancer patients that addresses this
important need.
MOLECULAR LANDSCAPE OF ADVANCED PROSTATE CANCER
Large-scale genomic analyses of metastatic prostate tumors have
demonstrated a high frequency of germline and somatic
alterations in several cancer-speciﬁc genes that are actionable or
currently being investigated as candidate predictive biomarkers
(Fig. 1) [6–9]. Some are more commonly seen in localized disease
such as SPOP mutations and ETS family gene fusions [10]. The
most common gene alterations enriched in CRPC, compared to
earlier disease states, include AR and TP53, which are present in
>50% of cases [6, 9]. Other commonly affected pathways with
important clinical and therapeutic implications include the PI3K
pathway genes such as PTEN-AKT-mTOR, and HRR genes such as
BRCA1/2, ATM which are altered in ~45%, ~25%, ~7-10% of CRPC
cases, respectively [6, 8]. Additional altered genes in CRPC include
those involved in the cell cycle (~30%) such as RB loss, CDKN1B,
and CCND1; epigenetic regulator genes (~25%) such as KMT2C,
KMT2D, and CHD1; WNT pathway genes (~15%) such as APC and
CTNNB1, CDK12 (~7%); and MAP kinase pathway genes (~5%)
[6, 8, 9]. These alterations in the context of drug development and
clinical decision-making are discussed in further detail in the next
section. Many of these alterations occur concurrently, and based
on prior reports, about 65–85% of analyzed CRPC tumors harbor
potentially actionable alterations beyond AR, deﬁned as the ability
to predict response to an available drug based on existing
preclinical data [6]. Structural variants in the non-protein-coding
regions also have a potential impact on the activity of important
regulators of cancer progression [9]. A recent whole-genome
sequencing analysis, the ﬁrst of its kind in CRPC, identiﬁed that
81% of cases harbored ampliﬁcation of a putative enhancer of AR,
which may drive androgen resistance [9, 11]. Structural variants
were also demonstrated near the MYC, TP53, CDK12, FOXA1, and
BRCA2 genes with potential biological and clinical implications.
In metastatic hormone-sensitive prostate cancer (mHSPC),
treatment options have rapidly expanded, yet decision-making is
based mainly on clinical factors without integration of genomic
biomarkers. A recent study describes potential biomarkers of
disease aggressiveness [7]. Speciﬁcally, alterations involving AR,
TP53, cell cycle, and MYC pathways predict for a shorter time to
castration resistance, while alterations in SPOP gene and WNT
pathway are associated with lower rate and longer time to
castration resistance [7]. Furthermore, in tumors with high-volume
(≥ 4 bone metastases and/or visceral metastasis) mHSPC, higher

fraction of alterations indicative of genomic instability, and
alterations involving cell cycle, epigenetic regulation, and NOTCH
pathways are seen. Thus, the development of a clinical-genomic
model for both mHSPC as well as CRPC represents a major unmet
medical need, for which a large number of patients are needed
with careful clinical and genomic annotation.
IMPLEMENTATION OF PRECISION MEDICINE IN PROSTATE
CANCER
Our understanding of the molecular landscape of advanced
prostate cancer provides a platform for the development of
targeted therapies, and for optimizing therapeutic combination
strategies and sequencing. Excitingly, intense investigation is
already taking place to leverage this knowledge and expand
therapeutic options for men with advanced prostate cancer.
Increasingly, genomic sequencing is also becoming a pre-requisite
for clinical trials, thus availability of routine genetic testing
becomes imperative to ensure patients have access to
biomarker-driven therapies and clinical trials.
Approximately 20–25% of men with mCRPC have germline or
somatic alterations involving HRR genes, such as BRCA1/2 and
ATM, which may predict for sensitivity to PARP inhibitors
and platinum agents [12]. Large clinical trials such as PROfound
and TRITON2 have led to the FDA approval of two PARP inhibitors,
olaparib and rucaparib, respectively, in men with mCRPC that
harbor deleterious somatic or germline mutations in HRR genes
[2, 3]. In May 2020, olaparib was approved for men with HRR genealtered CRPC while the rucaparib approval was restricted to
patients with tumors harboring alterations in BRCA1/2. Despite
these approvals, many questions remain about the relevance of
PARP inhibitors in patients harboring non-BRCA HRR genes. Many
of these questions can be answered with a real-world database
such as PROMISE. In addition to PARP inhibitors, exceptional
responses to platinum-based chemotherapy have also been
observed in BRCA2-mutant CRPC cases [13, 14]. However, not
much is known in this population about the utility of platinum
agents and PARP inhibitors in combination or as sequential
therapy. Other HRR gene targets under clinical development
include ATR inhibitors and ATM inhibitors. Of speciﬁc interest
within the HRR pathway is CDK12 loss, which has shown to
correspond with high focal tandem duplications and high
neoantigen burden, potentially sensitizing CDK12-altered tumors
to immune checkpoint blockade [15–17]. Thus, knowledge from
real-world datasets on the appropriate sequencing and outcomes
of taxane chemotherapy with PARP inhibitors in less common
subgroups of men with mCRPC such as ATM mutations or less
common HRR gene alterations is needed.
About 45% men with mCRPC harbor pathogenic genomic
alterations within the PI3K pathway. The majority of alterations
involving this pathway occur in the PTEN gene (~40%), which has
previously proven to be a difﬁcult target with single agents and is
associated with poor prognosis [18]. Preclinical data suggest that
PTEN/PI3K and AR pathways have reciprocal crosstalk, thus
targeting both pathways in combination may enhance therapeutic
efﬁcacy [19]. A phase II study of abiraterone acetate and AKT
inhibitor, ipatasertib, showed a clinical beneﬁt particularly in PTENdeﬁcient mCRPC [20]. In the primary analysis of the phase III study
of this combination (IPATential150, NCT03072238), combined AR
and AKT blockade provided an improved progression-free survival
in patients with mCRPC with PTEN loss, compared to AR blockade
alone [21]. Another target within this pathway is AKT1 gene, which
occurs in about 1% of mCRPC patients. AKT inhibitors exhibit
clinical activity in AKT-mutated breast cancer and other solid
tumors [22] and are currently in development for mCRPC
(NCT04087174). Other alterations of interest in this pathway
involve PIK3CA, PIK3C2B, BRAF, MAP2K1, and KRAS genes.
Recently the ﬁrst PI3KCA inhibitor, alpelisib, was approved for
Prostate Cancer and Prostatic Diseases
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Fig. 1 Large-scale genomic sequencing analyses of mCRPC. A List of three prospective genomic analyses of mCRPC samples. B Distribution
of non-androgen-receptor, actionable genomic pathway alterations. C Distribution of commonly expressed and actionable genomic
alterations. *Represent estimates based original article.
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PIK3CA-mutated breast cancer [23], a development that can
inform future clinical trial designs and treatment options for
advanced prostate cancer as well.
About 3–5% of patients with CRPC also have evidence of DNA
mismatch repair deﬁciency (dMMR) and/or microsatellite instability (MSH)-high that are found through immunohistochemistry to
evaluate for loss of MMR protein and/or DNA sequencing [24].
These patients tend to have tumors with a higher tumor
mutational burden (TMB), predicting response to immune
checkpoint blockade [25–28]. In 2017, based on data from ﬁve
multi-cohort, single-arm studies of MSH-H or dMMR advanced
solid tumors [29, 30], pembrolizumab received a tumor-agnostic
approval for patients who progressed on prior treatment and did
not have satisfactory alternative treatment options. Although this
study marked the ﬁrst time in oncology drug development that a
therapy was approved based on a speciﬁc biomarker irrespective
of tumor histology, very few patients with prostate cancer were
enrolled. Furthermore, it is not clear whether routine testing of
dMMR and/or MSI is being performed in most clinical practices to
identify this subset of prostate cancer patients. More recently,
tumor-agnostic pembrolizumab approval was expanded to
include tumors with high TMB [31].
In addition to potential actionable alterations discussed, multiinstitution clinical trials such as Targeted Agent and Proﬁling
Utilization Registry (TAPUR, NCT02693535) by American Society of
Clinical Oncology highlight the aims of understanding the safety
and efﬁcacy of novel targeted agents in advanced prostate cancer
and other malignancies. In addition, large registries of real-world
data are being built to identify novel targets. The American
Association of Cancer Research (AACR) has implemented Project
GENIE (Genomics Evidence Neoplasia Information Exchange),
which consist of real-world data among 19 leading cancer centers
in the world. Despite the robustness of these pan-cancer
platforms, the nuances of different clinical states of prostate
cancer will not be captured. To complement these efforts,
our consortium was developed to leverage the wealth of existing
clinical-genomic data to expand our understanding of prostate
cancer biology and to improve current therapeutic approaches. In
the remaining sections, we highlight some key clinical questions
that are present in routine practice to provide context into the
design, structure, and objectives of PROMISE.
CURRENT CHALLENGES IN PROSTATE CANCER AND
POTENTIAL SOLUTIONS
The last two decades have seen signiﬁcant new advancements in
the treatment of metastatic prostate cancer. Much wider
availability of next-generation sequencing (NGS) panels has made
it possible to individualize treatment options for a subset of
prostate cancer patients with speciﬁc tumor markers or alterations. These developments have created a plethora of new
questions, many of which may be answered though accumulation
of clinical and genomic data in a “real-world” dataset. The
following examples highlight current challenges in the treatment
of advanced prostate cancer as well as potential solutions and
strategies to overcome barriers to the realization of the true
promise of precision medicine in prostate cancer.
Sequencing of therapies in prostate cancer
With the evolution of multiple novel treatment options in mCRPC,
including novel hormonal agents and PARP inhibitors, as well as
the emergence of novel therapeutic classes such as PSMAtargeted radioligand therapies, there is increasingly a wealth of
options to offer patients in a disease space where only a couple of
decades ago there were relatively few [32, 33]. In this setting, the
questions about appropriate sequencing of therapies become

especially relevant, especially as most patients will not be able to
receive all available treatment options and decisions of which
therapies to prioritize earlier as opposed to later in the disease
course must be made by the treating physician. For instance, in
molecularly selected patients able to receive PARP inhibitors, what
is the most optimal way to sequence these agents with taxane
chemotherapy and should the sequencing of therapies be
impacted by mutation status? The PROMISE clinical-genomic
platform can help to generate initial data on potential positive and
negative predictive biomarkers to guide these types of therapeutic questions.
Novel treatment paradigms in mHSPC and impact on
subsequent treatment options
As novel treatment options are also introduced earlier in the
disease course of prostate cancer, such as novel androgen
receptor signaling inhibitors (ARSIs) [34–37], the natural history
of many patients with mCRPC progressing on these therapies
earlier in the disease course may also be altered. Do patients who
develop castrate-resistant disease while being treated with ARSIs
in the hormone-sensitive space subsequently have more aggressive and rapidly progressing CRPC? Do these patients subsequently respond to the standard of care treatment options
available for mCRPC similarly to prior populations of patients not
treated with these agents in the hormone-sensitive setting? Are
these patients more likely to develop treatment-emergent
neuroendocrine or small cell prostate cancer [38]? It is incumbent
on the prostate cancer research community to better understand
this natural history in light of new treatment paradigms. In this
dynamic and rapidly changing treatment space much of the
available clinical trial data used to guide treatment decisions may
reﬂect a very different patient population than the patients being
treated now. Serial cell-free DNA (cfDNA) is a cutting-edge
solution to temporally understand therapeutic resistance mechanisms and is expected to be widely adopted in the future.
Therefore, the vast genomic data gathered for each patient will
be invaluable in our efforts to answer questions related to
treatment exposure and acquisition of resistance.
Natural history and treatment options for novel molecular
subtypes in prostate cancer
As treatment for prostate cancer is increasingly individualized and
new biological subsets are identiﬁed through increased use of
NGS, it is also important to better deﬁne the natural history
of these patient populations. The molecular characterization of
exceptional responders and non-responders to standard of care
therapies will help better deﬁne molecular predictive biomarkers.
In addition, as of 2020 there are now two agents, olaparib and
rucaparib, speciﬁcally approved for the treatment of mCRPC with
HRR alterations [2, 3] as well as multiple clinical trial options for
patients with advanced prostate cancer and various genomic
alterations. This is particularly important since response to
standard of care treatments will serve as a benchmark for the
efﬁcacy of novel therapies that speciﬁcally target these genomic
alterations. These questions need to be answered in order for
precision medicine to truly fulﬁll its promise. More individualized
treatment, implying the division of the broad diagnosis of prostate
cancer into ever smaller molecularly deﬁned subsets, will
increasingly help guide the rational design of clinical trials and
therapy selection. One early example of this approach is the
IND.234 trial (NCT03385655) from the Canadian Clinical Trials
group that uses a cfDNA platform to select therapy in prostate
cancer. The improved understanding of these molecularly deﬁned
subsets through hypothesis-generating retrospective studies can
help improve the design of biomarker-driven clinical trials of
prostate cancer.
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Impact of race/ethnicity or socioeconomic status on prostate
cancer treatments and outcomes
Many studies focusing on characterizing the molecular alterations in prostate cancer have included a very limited number of
ethnically diverse subsets of patients. Understanding how race/
ethnicity impacts genomic proﬁle and response to therapy is
critical to bridging the disparities gap in men with prostate
cancer. Real-world data from this platform can ﬁll this gap. Black
men remain underrepresented in phase 3 trials in prostate
cancer despite being disproportionately impacted by lethal
prostate cancer [39] and despite evidence of perhaps superior
outcomes when treated with sipuleucel-T or docetaxel [40, 41].
Do these factors impact the diagnostic decisions made, such as
the choice of imaging in advanced prostate cancer [42]? Are
certain treatment options chosen preferentially over others and
does this create healthcare inequities? Among the treatment
options chosen, do certain options work better for certain
subsets of patients? Such questions are difﬁcult to answer with
clinical trials which historically underrepresent many of the
populations in question [43]. However, it is absolutely vital to
answer these questions in order to help us improve the care of
all patients with advanced prostate cancer. The collection of
germline data for the patients in a real-world dataset will also
help to both understand the landscape of somatic and germline
mutations in underrepresented patients and the general
availability of germline testing in this patient population
[44, 45].
UTILITY OF REAL-WORLD DATA AND THE UNMET NEED FOR
THE PROMISE CONSORTIUM
All of the above clinical questions and scenarios in advanced
prostate cancer illustrate the importance and potential utility of a
large and well-maintained real-world database that serves as a
repository for clinical and genomic data of prostate cancer patients.

There are several pertinent reasons necessitating such a database
as an important clinical research tool in advanced prostate cancer.
Prospective randomized clinical trials remain the gold standard
in clinical cancer research and shape the current standard of care.
While prospective clinical trials capture data on efﬁcacy, observational studies can help to better understand effectiveness of the
treatments in the real-world setting. Importantly, most prostate
cancer patients do not get their cancer treatment as part of a
clinical trial. A recent study estimated that only about 8% of
oncology patients enroll in a clinical trial [46]. Consequently, the
experiences and treatment outcomes of most prostate cancer
patients are not systematically recorded or analyzed. In addition,
most clinical trial datasets do not capture the entirety of patient
experience from diagnosis until ﬁnal treatments, focusing rather
on one speciﬁc treatment outcome, and thus provide only a
limited window into the outcomes of patients in the real-world
setting. Retrospective studies of real-world patient datasets that
include well-annotated clinical and genomic data can shed light
on important questions that may be difﬁcult to address in
prospective clinical trials.
The inclusion of underrepresented minorities in this dataset is
one of the important missions of this consortium. Data from
retrospective series can more extensively capture clinical outcomes and other information of more diverse populations,
including minority populations underrepresented in clinical trials.
The low participation rates of patients who identify as underrepresented minorities in clinical trials of prostate cancer have
been well documented and remain a signiﬁcant challenge in
clinical research and the conduct of trials [43]. The reasons for this
are complex and multifactorial but it remains a signiﬁcant
challenge that is yet to be addressed. The selection for this
consortium of diverse clinical sites representing different geographic regions of the United States that serve unique underrepresented patient populations is certainly an important step
toward bridging the cancer genomics disparities gap in prostate

Fig. 2 PROMISE consortium structure and workﬂow. A Structure consisting of administrative headquarters, bio-informatics committee,
executive committee, data committee, diversity & inclusion committee, and patient advocacy committee. Responsibilities of each committed
listed. B Project workﬂow from data collection to release of data in abstract/manuscript form.
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DEVELOPMENT OF PROMISE, ITS AIMS, AND THE INCLUSION
OF A DEDICATED BIO-INFORMATICS COMMITTEE
The PROMISE consortium was formed with the recognition of the
signiﬁcant clinical and research needs of linking clinical and
genomic data to outcomes, in order to better inform treatment
decisions and outcomes for patients with advanced prostate
cancer. Data collected in this consortium will address signiﬁcant
knowledge gaps that come about as the underlying biology of
prostate cancer becomes better understood and multiple novel
agents and classes of drugs emerge as treatment options. The
structure of the PROMISE consortium including all of the
committees and the ﬂow chart of data analysis are shown in Fig. 2.
PROMISE is currently a consortium of 16 academic institutions
with the common goal of understanding the real-world data in
patients with advanced prostate cancer. The goal is to expand the
reach of this database to include academic institutions and
community practices. The consortium has two main aims:
(1) To establish a large, diverse, inclusive, and well-annotated
repository of completely de-identiﬁed clinical and genomic

Table 1.

cancer. Many of the initially proposed projects focus on questions
related to racial disparities.
It is also important to keep in mind that although randomized
clinical trials remain the gold standard for generating clinical data,
many relevant clinical questions are initially asked in hypothesisgenerating retrospective studies. Important descriptive data of the
natural history of disease in these speciﬁc subgroups can be
obtained through retrospective chart review. Many important
prognostic and predictive markers and biomarkers of interest can
initially be identiﬁed through analyses of real-world data and are
subsequently validated prospectively. Furthermore, in contrast to
prospective clinical trials where treatment options are prespeciﬁed, retrospective observational studies can also attempt to
capture clinical decision-making, such as decisions made based on
the results of genomic testing. In databases with large numbers of
patients and well-annotated clinical and genomic data, important
insights can be gleaned from this approach.
As treatments are increasingly individualized for molecularly
selected subsets of patients with mCRPC, the careful collection of
genomic data in large real-world cohorts can also help shed light
on tumor biology and help advance questions that produce
important validation studies. The availability of multiple tissue or
blood samples from the same patient can also be particularly
instructive. This information can help better deﬁne the evolution
of molecular alterations or other biomarkers in the tumor
throughout the course of disease progression. The understanding
of such changes obtained from serial sampling of either repeat
solid biopsies or of repeated cfDNA sampling can also help deﬁne
the changes in the tumor that happen during progression on
speciﬁc treatments. Further important comparisons can be drawn
in the molecular alterations and other biomarkers detected in
solid biopsies and cfDNA in the same patient.
Overall, our long-term goal is to develop a large real-world
dataset collected from institutions including both academic and
large community-based hospital systems, which by deﬁnition will
be both heterogeneous and also more representative of realworld trends. Clinical and genomic information from many
patients who are unable or unwilling to be treated on a clinical
trial due to clinical, logistical or other reasons will also be
included. This will make potential ﬁndings more generalizable
relative to the data obtained from carefully selected clinical trial
populations. The patient population included in a real-world
dataset will also reﬂect the diversity of treatment options and
strategies employed, diagnostic and genomic testing used, and
the diverse patient populations across the different geographic
regions.

Class of alteration
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Table 2. Current Institutions Participating in the PROMISE
Consortium.
Institution name

Location

City of Hope

Duarte, CA

Duke Cancer Institute

Durham, NC

Emory University

Atlanta, GA

Henry Ford Health System

Detroit, MI

Icahn School of Medicine at Mount Sinai

New York, NY

Johns Hopkins University School of Medicine

Baltimore, MD

Karmanos Cancer Center

Detroit, MI

Medical College of Wisconsin

Milwaukee, WI

Tulane University

New Orleans, LA

University of California San Diego

San Diego, CA

University of California San Francisco

San Francisco, CA

University of Iowa

Iowa City, IA

University of Michigan

Ann Arbor, MI

University of Oklahoma

Oklahoma City, OK

University of Washington

Seattle, WA

Weil Cornell Medical Center

New York, NY

patient data that is linked to clinical characteristics and diseaserelated outcomes.
(2) To investigate prognostic and potentially predictive biomarkers in patients with advanced prostate cancer treated with
approved therapies including genomic, transcriptomic, and
proteomic biomarkers.
Inclusion criteria for patients in this dataset consist of having
advanced prostate cancer with either mHSPC or castrate-resistant
prostate cancer (CRPC). In addition, patients should have undergone prior germline and/or somatic tumor molecular proﬁling
studies including, but not limited to, one or more of the following
blood or tissue-based assays: tumor DNA sequencing (e.g., cellfree circulating tumor DNA or tumor tissue sequencing), germline
DNA sequencing and transcript proﬁling studies (e.g., RNA-seq,
qRT-PCR). In total, consecutive patients with available clinical and
genomic data at each site will be included to limit selection bias.
Clinical and treatment data is collected from the time of initial
prostate cancer diagnosis (Table 1). All data are maintained in a
secure RedCap database and is completely deidentiﬁed without
any protected health information. Genomic information entered
into the database from both solid tissue and liquid biopsy testing
and inclusive of both somatic and germline alterations are
formatted to standardized criteria and reviewed by the bioinformatics committee. We will only include the entries that have
all available data related to clinical outcomes and genomic
sequencing.
PROMISE CONSORTIUM INSTITUTIONS, DATA ACQUISITION
PLAN, AND MISSION STATEMENT
The PROMISE consortium participating institutions are listed in
Table 2. The consortium was formed in the ﬁrst half of 2020 and
data entry to the consortium has since risen steadily as sites have
come onboard and over 1000 patient records are anticipated by
early 2021 (Fig. 3). Genomic data are being audited for accuracy at
each institution.
The mission of the PROMISE consortium is to investigate the
outcomes of patients with advanced prostate cancer who have
genomic and molecular proﬁling information and therefore to
bridge the knowledge gap between real-world genomic data and
clinical outcomes in patients with advanced prostate cancer.
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Fig. 3 Project milestones and future timeline. The PROMISE
consortium was formed in March 2020. At the end of 2020, we
collected clinical data of over 700 patients. We anticipate clinical
data collection of 2000 patients by the end of 2021.

Consortium structure will also provide signiﬁcant opportunities for
mentorship of junior investigators and trainees. The consortium
will plan to pursue multiple projects addressing speciﬁc questions
which are proposed by the participating site investigators and
selected through scientiﬁc review by the executive committee
with priority given to projects proposed by junior investigators
and trainees. Given the important potential contribution of
evaluating outcomes in a more diverse population than that
represented in clinical trials, a subcommittee for diversity and
inclusion has been created with a plan to implement strategies to
increase diversity if the database fails to maintain a balanced
population.
FUTURE DIRECTIONS
In a short period of time, we have gathered vast amounts of
clinico-genomic information to answer important clinical questions. We are looking forward to expand our database to include
many more academic institutions and community practices to
make our patient population more representative of the realworld setting. In addition, once the database becomes robust for
large-scale analyses, these data may be made publicly available for
future research, following efforts such as cBioportal. Lastly, there is
a long-term plan to develop infrastructure for blood- and tissue
biorepository to perform molecular analyses.
CONCLUSIONS
Precision medicine holds signiﬁcant promise for helping to
individualize treatment approaches for patients with advanced
prostate cancer and to help understand the underlying mechanisms of this heterogeneous disease. The PROMISE consortium is an
important new collaboration among leading academic centers in
the United States that aims to bridge the gap between clinical and
genomic information for patients with metastatic prostate cancer
and available genomic data from commercial and institutional
assays. The well-annotated, de-identiﬁed patient data collected for
this consortium will be leveraged to help answer speciﬁc
questions and guide projects proposed by the consortium
members. Genomic data entered into the database will be vetted
by a bioinformatician and individual projects approved by the
executive committee as part of the consortium structure. This
organized approach will help to address important questions at
the intersection of clinical and genomic data that are most
optimally addressed using a real-world dataset. It is our hope that
this approach will eventually help to improve outcomes for
patients with advanced prostate cancer.

V.S. Koshkin et al.

8
REFERENCES
1. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al.
Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant
prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol.
2017;71:151–4.
2. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for
metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091–102.
3. Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a
BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020;38:3763–72.
4. Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS. Germline and
somatic mutations in prostate cancer for the clinician. J Natl Compr Canc Netw.
2019;17:515–21.
5. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited
DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J
Med. 2016;375:443–53.
6. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al.
Integrative clinical genomics of advanced prostate cancer. Cell.
2015;161:1215–28.
7. Stopsack KH, Nandakumar S, Wibmer AG, Haywood S, Weg ES, Barnett ES, et al.
Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic
castration-sensitive prostate cancer. Clin Cancer Res. 2020;26:3230–8.
8. Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA.
2019;116:11428–36.
9. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, et al. Genomic
hallmarks and structural variation in metastatic prostate. Cancer Cell.
2018;174:758–69.e9.
10. Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary
Prostate Cancer. Cell. 2015;163:1011–25.
11. Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, et al.
Structural alterations driving castration-resistant prostate cancer revealed by
linked-read genome sequencing. Cell. 2018;174:433–47.e19.
12. Mota JM, Barnett E, Nauseef JT, Nguyen B, Stopsack KH, Wibmer A, et al.
Platinum-based chemotherapy in metastatic prostate cancer with DNA repair
gene alterations. JCO Precis Oncol. 2020;4:355–66.
13. Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Biallelic inactivation
of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer.
Eur Urol. 2016;69:992–5.
14. Zafeiriou Z, Bianchini D, Chandler R, Rescigno P, Yuan W, Carreira S, et al.
Genomic analysis of three metastatic prostate cancer patients with exceptional
responses to carboplatin indicating different types of DNA repair deﬁciency. Eur
Urol. 2019;75:184–92.
15. Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, et al. Inactivation of
CDK12 delineates a distinct immunogenic class of advanced prostate. Cancer
Cell. 2018;173:1770–82.e14.
16. Nguyen B, Mota JM, Nandakumar S, Stopsack KH, Weg E, Rathkopf D, et al. Pancancer analysis of <em>CDK12</em> alterations identiﬁes a subset of prostate
cancers with distinct genomic and clinical characteristics. Eur Urol.
2020;78:671–9.
17. Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, et al. CDK12-mutated
prostate cancer: clinical outcomes with standard therapies and immune checkpoint blockade. JCO Precis Oncol. 2020;4:382–92.
18. George DJ, Halabi S, Healy P, Jonasch D, Anand M, Rasmussen J, et al. Phase 2
clinical trial of TORC1 inhibition with everolimus in men with metastatic
castration-resistant prostate cancer. Urol Oncol. 2020;38:79.e15–79.e22.
19. Crumbaker M, Khoja L, Joshua AM. AR signaling and the PI3K pathway in prostate
cancer. Cancers. 2017;9:34.
20. de Bono JS, De Giorgi U, Rodrigues DN, Massard C, Bracarda S, Font A, et al.
Randomized Phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and
without PTEN loss. Clin Cancer Res. 2019;25:928–36.
21. de Bono JS, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, et al. LBA4
IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC).
Ann Oncol. 2020;31:S1153–S4.
22. Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, et al. AKT
inhibition in solid tumors with AKT1 mutations. J Clin Oncol. 2017;35:2251–9.
23. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for
PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J
Med. 2019;380:1929–40.
24. Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, et al.
Immunogenomic analyses associate immunological alterations with mismatch
repair defects in prostate cancer. J Clin Investig. 2018;128:4441–53.

25. Graham LS, Montgomery B, Cheng HH, Yu EY, Nelson PS, Pritchard C, et al.
Mismatch repair deﬁciency in metastatic prostate cancer: response to PD-1
blockade and standard therapies. PLoS ONE. 2020;15:e0233260.
26. Ritch E, Fu SYF, Herberts C, Wang G, Warner EW, Schönlau E, et al. Identiﬁcation of
hypermutation and defective mismatch repair in ctDNA from metastatic prostate
cancer. Clin Cancer Res. 2020;26:1114–25.
27. Antonarakis ES, Shaukat F, Isaacsson Velho P, Kaur H, Shenderov E, Pardoll DM,
et al. Clinical features and therapeutic outcomes in men with advanced
prostate cancer and DNA mismatch repair gene mutations. Eur Urol.
2019;75:378–82.
28. Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, et al. Analysis of
the prevalence of microsatellite instability in prostate cancer and response to
immune checkpoint blockade. JAMA Oncol. 2019;5:471–8.
29. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch
repair deﬁciency predicts response of solid tumors to PD-1 blockade. Science.
2017;357:409–13.
30. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin
Cancer Res. 2019;25:3753–8.
31. Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al.
Association of tumour mutational burden with outcomes in patients with
advanced solid tumours treated with pembrolizumab: prospective biomarker
analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet
Oncol. 2020;21:1353–65.
32. Hofman MS, Emmett L, Violet J, AYZ, Lawrence NJ, Stockler M, et al. TheraP: a
randomized phase 2 trial of (177) Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial
Protocol ANZUP 1603). BJU Int. 2019;124 Suppl 1:5–13.
33. Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]PSMA-617 radionuclide treatment in patients with metastatic castration-resistant
prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet
Oncol. 2018;19:825–33.
34. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al.
ARCHES: a randomized, phase III study of androgen deprivation therapy with
enzalutamide or placebo in men with metastatic hormone-sensitive prostate
cancer. J Clin Oncol. 2019;37:2974–86.
35. Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R,
et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J
Med. 2019;381:13–24.
36. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al.
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N
Engl J Med. 2017;377:352–60.
37. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al.
Abiraterone for prostate cancer not previously treated with hormone therapy. N
Engl J Med. 2017;377:338–51.
38. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and
genomic characterization of treatment-emergent small-cell neuroendocrine
prostate cancer: a multi-institutional prospective study. J Clin Oncol.
2018;36:2492–503.
39. Spratt DE, Chen YW, Mahal BA, Osborne JR, Zhao SG, Morgan TM, et al. Individual
patient data analysis of randomized clinical trials: impact of black race on
castration-resistant prostate cancer outcomes. Eur Urol Focus. 2016;2:532–9.
40. Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF,
et al. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis.
2020;23:517–26.
41. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM Jr., et al.
Overall survival of Black and White men with metastatic castration-resistant
prostate cancer treated with docetaxel. J Clin Oncol. 2019;37:403–10.
42. Bucknor MD, Lichtensztajn DY, Lin TK, Borno HT, Gomez SL, Hope TA. Disparities
in PET imaging for prostate cancer at a tertiary academic medical center. J Nucl
Med. 2020;62:695–9.
43. Balakrishnan AS, Palmer NR, Fergus KB, Gaither TW, Baradaran N, Ndoye M, et al.
Minority recruitment trends in phase III prostate cancer clinical trials (2003 to
2014): progress and critical areas for improvement. J Urol. 2019;201:259–67.
44. Kwon DH, Borno HT, Cheng HH, Zhou AY, Small EJ. Ethnic disparities among men
with prostate cancer undergoing germline testing. Urol Oncol. 2020;38:80.e1–e7.
45. Mahal BA, Alshalalfa M, Kensler KH, Chowdhury-Paulino I, Kantoff P, Mucci LA,
et al. Racial differences in genomic proﬁling of prostate cancer. N Engl J Med.
2020;383:1083–5.
46. Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic review
and meta-analysis of the magnitude of structural, clinical, and physician and
patient barriers to cancer clinical trial participation. J Natl Cancer Inst.
2019;111:245–55.

Prostate Cancer and Prostatic Diseases

V.S. Koshkin et al.

9
AUTHOR CONTRIBUTIONS
VK, VP, AA, and RM article conceptualization; all authors including VK, VP, AA, and RM
manuscript writing.

FUNDING
Currently, each site principal investigator is funding their own efforts for the
consortium. In the future, we will be evaluating outside funding opportunities from
organizations such as the Prostate Cancer Foundation and industry sources.

COMPETING INTERESTS
VSK received research funding to his institution from Janssen, Nektar, Endocyte,
Clovis. He has received compensation as a member of the scientiﬁc advisory board of
Janssen, Clovis, Pﬁzer, Seattle Genetics/Astellas, Dendreon, AstraZeneca, EMD Serono.
All funding received is for work performed outside the scope of this study. MAB
received research funding to his institution from Xencor, Bayer, Bristol-Myers Squibb,
Genentech/Roche, Seattle Genetics, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pﬁzer. He has received
compensation as a member of the scientiﬁc advisory board or as paid consultant of
Exelixis, Bayer, BMS, Eisai, Pﬁzer, AstraZeneca, Janssen, Calithera Biosciences,
Genomic Health, Nektar, and Sanoﬁ. All funding received is for work performed
outside the scope of this study. CP has consulted for AstraZaneca and received
compensation for work performed outside the scope of this study. AT received
research funding to his institution from EMD Serono, Aravive Inc, and Wndmil
therapeutics. He has received compensation as a member of the scientiﬁc advisory
board of Exilixis, EMD Serono, Genzyme, Foundation, and Pﬁzer. All funding received
is for work performed outside the scope of this study. PB received research funding
to his institution from AstraZeneca, Merck, Blue Earth Diagnostics. He has received
compensation as a member of the scientiﬁc advisory board of Bristol Myers Squibb,
Exelexis, Janseen, Pﬁzer, Sanoﬁ, Dendreon, Caris, Bayer, EMD Serono. All funding
received is for work performed outside the scope of this study. CH received research
funding to his institution from AstraZeneca, Bayer, Dendreon, Merck. She has stock
ownership in Johnson & Johnson. All funding received is for work performed outside
the scope of this study. WO is an employee of Sema4 as Chief Medical Science Ofﬁcer.
He has consulted for and received funding from Amgen, Astellas, Bayer, AstraZeneca,
Genzyme, Janssen, and Pﬁzer. All funding received is for work performed outside the
scope of this study. EH received research funding to her institution from Caris. She
has consulted for and received compensation from Caris. All funding received is for
work performed outside the scope of this study. CHM is an employee of McGraw Hill.
She has consulted for and received compensation from Dendreon and Bayer. All
funding received is for work performed outside the scope of this study. STT received
research funding to his institution from Sanoﬁ, Medivation, Astellas, Janssen,
rogenics, Dendreon, Newlink, Inovio, Immunomedics, Atlab, Boehringer Ingelheim,
Millennium, Bayer, Merck, Abbvie, Karyopharm, Endocyte, Clovis, and Novartis. He has
received personal honoraria from Sanoﬁ, Medivation/Astellas, Dendreon, Janssen,
Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, Abbvie, Tolmar,
Seattle Genetics, Amgen, Clovis, QED, Pﬁzer, AAA/Novartis, Genomic Health, POINT
Biopharma, Blue Earth Diagnostics. All funding received is for work performed

Prostate Cancer and Prostatic Diseases

outside the scope of this study. MTS received research funding to his institution from
Zenith Epigenetics, Bristol Myers Squibb, Merck, Immunomedics, Janssen, AstraZeneca, Pﬁzer, Madison Vaccines, Tmunity and Hoffman-La Roche. He has consulted for
and received compensation from Janssen and Resverlogix. All funding received is for
work performed outside the scope of this study. A Armstrong received research
funding to his institution from Merck, Bayer, Pﬁzer, Astellas, Janssen, Genentech/
Roche, Constellation, Beigene, BMS, AstraZeneca. He consulted for and received
compensation from Merck, Bayer, Pﬁzer, Astellas, Janssen, AstraZeneca, and Clovis. All
funding received is for work performed outside the scope of this study. A Alva
received research funding to his institution from MSD, AstraZeneca, Bristol-Myers
Squibb, Astellas, Seattle Genetics, Genentech, Pﬁzer, Progenics, Prometheus, Eli Lilly,
ASCO, Celgene, and Harpoon Therapeutics. He has received compensation as a
member of the advisory board and as paid consultant for MSD, Bristol-Myers Squibb,
AstraZeneca, Genentech, Roche, Pﬁzer, Progenics, and Prometheus. All funding
received is for work performed outside the scope of this study. RM received research
funding to her institution from Bayer, Pﬁzer, and Tempus. She has received
compensation as a member of the advisory board for AstraZeneca, Bayer, Bristol
Myers Squibb, Calithera, Exelixis, Janssen, Merck, Novartis, Pﬁzer, Sanoﬁ, and Tempus.
She consulted for and received compensation for Dendreon and Vividion. She serves
on the molecular tumor board at Caris. All funding received is for work performed
outside the scope of this study. VGP, A Ali, DR, JJP, OK, MC, JS, AC, LB, ML, LSG, SN, AJ,
SRC, RG, LA, AP, TJ, DN, CN, DK, MP, BT, FC, AM, SH, and TD have no competing
interests to disclose.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to R.M.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.

© The Author(s) 2021

